Subscribe to
this category


A total of 24 posts are filed under Strategy
Economies of Rare
Economies of scale are the efficiencies unlocked by large numbers. I’ve come to realize that the efficiencies of scale can emerge at the… Continue Reading
Invitae Expands Network of Patients in Rare and Ultra-Rare Patient Registries
Rare Daily Staff Invitae said it is expanding its network of rare and ultra-rare patient registries to include five additional… Continue Reading
Shire Adopts Open Access Policy for Publication of Company-Supported Research
Rare Daily Staff The rare disease drug company Shire said it has implemented a new publication policy requiring the submission of all… Continue Reading
Alnylam Expands Access Program to Include Free Genetic Testing for People at Risk for AHPs
Rare Daily Staff Alnylam Pharmaceuticals said it has expanded the Alnylam Act program to include no-charge, third-party genetic testing and… Continue Reading
Spark Prices Gene Therapy for Eye Disease at $850,000, Introduces Outcomes-Based Rebates
Rare Daily Staff Spark Therapeutics said it would charge $850,000 for Luxturna, its gene therapy to treat a certain form of an inherited eye… Continue Reading
Alexion and Hedge Fund Elliott Management Agree to Collaborate on Identifying a New Board Member
Rare Daily Staff Alexion Pharmaceuticals said today that its board of directors and shareholder Elliott Management have agreed to work… Continue Reading
Array Spins Out Yarra Therapeutics to Develop Drugs for Rare Diseases
Rare Daily Staff Array BioPharma, in a filing with the U.S. Securities and Exchange Commission, said it spun out its experimental therapy to… Continue Reading